J. Horobin

British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update).

M. Lomer, M. Williams, L. Seamark, 2016, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, K. Fukuoka, L. Vaickus, 2016, Cancer Chemotherapy and Pharmacology.

Design Considerations for Clinical Trials Using the Cutaneous Dermatomyositis Disease Area and Severity Index as a Primary Endpoint

V. Werth, D. Fiorentino, J. Horobin, 2017 .

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Marilyn M. Li, T. Burns, S. Ramalingam, 2019, Lung cancer.

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.

Suzanne F. Jones, H. Burris, J. Infante, 2014 .

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .